Efficacy and safety of rituximab in moderately‐to‐severely active systemic lupus erythematosus: The randomized, double‐blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial
Arthritis & Rheumatism2009Vol. 62(1), pp. 222–233
Citations Over TimeTop 1% of 2009 papers
Joan T. Merrill, C. Michael Neuwelt, Daniel J. Wallace, Joseph C. Shanahan, Kevin Latinis, Jim C. Oates, Tammy O. Utset, Caroline Gordon, David Isenberg, Hsin‐Ju Hsieh, David Zhang, Paul Brunetta
Abstract
The EXPLORER trial enrolled patients with moderately-to-severely active SLE and used aggressive background treatment and sensitive cutoffs for nonresponse. No differences were noted between placebo and rituximab in the primary and secondary end points. Further evaluation of patient subsets, biomarkers, and exploratory outcome models may improve the design of future SLE clinical trials.
Related Papers
- → Randomized trial of azathioprine or prednisone for initial immunosuppressive treatment of myasthenia gravis(1997)67 cited
- → Azathioprine plus prednisone in treatment of pemphigoid.(1978)94 cited
- → A randomised clinical trial comparing prednisone and azathioprine in myasthenia gravis. Results of the second interim analysis. Myasthenia Gravis Clinical Study Group.(1993)75 cited
- → Comparison of Azathioprine, Prednisone, and Heparin Alone or Combined in Treating Lupus nephritis(1973)148 cited
- → SUCCESSFUL IMMUNOSUPPRESSIVE TREATMENT OF OLIGURIC EXTRACAPILLARY GLOMERULONEPHRITIS(1974)10 cited